FRIDAY 26 APRIL 2019 | 09:00-17:15

  • Course directors: A. Bossi (FR) and G. De Meerleer (BE)
     

Course aim

To provide an up-date of the current challenges related to the diagnosis and management of High Risk prostate cancer patients with specific emphasis on the role of EBRT and brachytherapy, whether or not within a multimodality approach.
 

Learning objectives

The most important learning objective will be to recognise the need of a fully multidisciplinary approach in the diagnosis and treatment of patients diagnosed with High risk Prostate cancer. 
In details, after participating to this course attendees will be able:

  • to summarise the current evidences related to the recent definition and diagnosis of High risk disease. 
  • to discuss the modern treatment options. 
  • to explain the rapidly changing paradigm in the association between drugs and irradiation 
  • to identify the most frequent toxicity related to the different management options. 
  • to discuss the current and future treatment approaches.
     

Target audience

Radiation oncologists, surgeons with a special interest in urology, medical oncologists, RT physicists, RTTs and RT nurses.


Programme
 

Time slot

Title

Teacher

09:00

Pre-meeting starts

 

09:00-09:30

The definition of HRPCa in 2019

S. Joniau (BE)

09:30-10:00

Local and distant staging of HRPCa: the role of MRI

R. Renard-Penna (FR)

10:00-10:30

Beyond Gleason score and PSA

A. Briganti (IT)

10:30-11:00

COFFEE BREAK

11:00-11:15

External Beam RT

V. Fonteyne (BE)

11:15-11:30

Surgery

S. Joniau (BE)

11:30-11:45

Brachytherapy

P. Hoskin (UK)

11:45-12:00

Alternative fractionations

C. Cozzarini (IT)

12:00-12:15

Discussion

 

12:15-12:30

Clinical cases discussion

G. De Meerleer (BE) / A. Bossi (FR)

12:30-14:00

LUNCH

14:00-14:20

Imaging for the relapsing patient

R. Renard-Penna (FR)

14:20-14:40

Post-op RT

C. Cozzarini (IT)

14:40-15:00

Salvage surgery

A. Briganti (IT)

15:00-15:20

Salvage brachytherapy

P. Hoskin (UK)

15:30-16:00

COFFEE BREAK

16:00-16:15

The oligometastatic disease: what are we talking about?

A. Briganti (IT)

16:15-16:30

State of the art of RT in the oligometastatic setting

V. Fonteyne (BE)

16:30-16:45

Treatment of Up-front M+ disease

S. Joniau (BE) and C. Cozzarini (IT)

16:45-17:00

Discussion

 

17:00-17:15

Clinical cases discussion

G. De Meerleer (BE) / A. Bossi (FR)

17:15

Close of pre-meeting

G. De Meerleer (BE) / A. Bossi (FR)